Please login to the form below

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

Biogen’s R&D chief Ehlers heads for the exit

Biogen is heavily reliant on its wider MS portfolio, and a slew of newly launched or anticipated rival therapies like Novartis’ Mayzent (ozanimod) and Roche’s Ocrevus (ocelizumab) are already threatening

Latest news

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Also coming through the pipeline is Biogen’s Tecfidera follow-up diroximel fumarate (BIIB098), Novartis’ new antibody ofatumumab, and Celgene’s S1P receptor modulator ozanimod that is due for regulatory decision
BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Fedratinib was one of the late-stage development programmes highlighted by BMS when the merger was announced in January, although others – such as multiple sclerosis drug ozanimod and CAR-T cancer
Triplet approvals for myeloma boost Celgene in Q2

Also nearing the market are fedratinib for myelofibrosis which could be approved in September, luspatercept for myelodysplastic syndromes – with an FDA decision due next April – and ozanimod for multiple sclerosis, which
Post-merger Celgene to lead pharma growth

Celgene also has five potential blockbusters in its late-stage pipeline, including MS treatment ozanimod and myelodysplastic syndromes/beta thalassemia candidate luspatercept, which have both recently been filed.
Celgene files luspatercept ahead of key merger vote

The drug is one of five late-stage pipeline drugs from Celgene tipped for blockbuster status (the first being the just-re-filed ozanimod) and the filing comes just days ahead

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Pharma deals in July 2015

Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer, MedComms Agency: Salary TBC

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Director or Senior Account Director: Salary TBC

Vice President: Competitive Salary Offered

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Consultant: competitive salary

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...